Quick Takeaways
- LYEL - Lyell Immunopharma, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity -87%.
- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Lyell Immunopharma, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- LYEL on Nasdaq
- Location
- South San Francisco, CA
- Fiscal year end
- 31 December
- Latest financial report
- 12 Mar 2026
What Changed
- Return On Equity YoY change: <span class="text-green-600">+32%</span>.
- Most recent SEC facts end date: 09 Mar 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-03-09) highlights Return On Equity -87.0%, Return On Assets -66.1%, and Operating Margin -748344.4%.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
34.1/100
Weak Confidence medium
Return On Equity
-87%
Metric score 0.0/100
Return On Assets
-66%
Metric score 0.0/100
Financial Health
- Current Ratio
- 5.28x
- Debt to Equity
- 0.29x
Strengths
Debt-to-equity and NetIncomeLoss YoY
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Key metrics snapshot
Return On Equity
-87%
YoY: +32%
Industry median: -43% (n=675)
Return On Assets
-66%
YoY: +19%
Industry median: -47% (n=673)
Operating Margin
-748344%
YoY: +27%
Industry median: -121% (n=298)
Current Ratio
5.28x
YoY: -25%
Industry median: 3.39x (n=667)
Debt-to-equity
0.29x
YoY: +60%
Industry median: 0.26x (n=530)
Revenues YoY
-41%
YoY:
Industry median: 7.3% (n=302)
NetIncomeLoss YoY
20%
YoY:
Industry median: -0.93% (n=641)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -87% | +32% |
| Return On Assets | -66% | +19% |
| Operating Margin | -748344% | +27% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 5.28x | -25% |
| Debt-to-equity | 0.29x | +60% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | -41% | |
| NetIncomeLoss YoY | 20% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 23,307,143 | -92% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY